{"id":45329,"date":"2017-09-29T08:05:01","date_gmt":"2017-09-29T12:35:01","guid":{"rendered":"http:\/\/piel-l.org\/blog\/?p=45329"},"modified":"2017-09-29T13:35:10","modified_gmt":"2017-09-29T18:05:10","slug":"european-dermatology-forum-guideline-for-the-treatment-of-androgenetic-alopecia-in-women-and-in-men-developed-by-the-guideline-subcommittee-androgenetic-alopecia-of-the-european-derm","status":"publish","type":"post","link":"https:\/\/piel-l.org\/blog\/45329","title":{"rendered":"European Dermatology Forum Guideline for the Treatment of Androgenetic Alopecia in Women and in Men Developed by the Guideline Subcommittee \u201cAndrogenetic Alopecia\u201d of the European Dermatology Forum"},"content":{"rendered":"<p><!--more--><\/p>\n<p><strong>European Dermatology Forum Guideline for the Treatment of Androgenetic Alopecia in Women and in Men Developed by the Guideline Subcommittee \u201cAndrogenetic Alopecia\u201d of the European Dermatology Forum European Dermatology Forum &#8211; 2017. <\/strong><\/p>\n<p>European Dermatology Forum (EDF) presenta una completa gu\u00eda en la que se describe la etiolog\u00eda, fisiopatolog\u00eda y epidemiolog\u00eda de la alopecia androg\u00e9nica. El documento brinda recomendaciones para el diagn\u00f3stico y lineamientos pormenorizados sobre las diferentes opciones terap\u00e9uticas.<\/p>\n<p> <strong>ABSTRACT<\/strong><br \/>\nAndrogenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80% Caucasian men and 42% of women. Patients afflicted with androgenetic alopecia may undergo significant impairment of quality of life. The European Dermatology Forum (EDF) initiated a project to develop evidence-based guidelines for the treatment of androgenetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia. <\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":16,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"class_list":["post-45329","post","type-post","status-publish","format-standard","","category-articulos-cientificos"],"_links":{"self":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/45329","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/comments?post=45329"}],"version-history":[{"count":0,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/45329\/revisions"}],"wp:attachment":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media?parent=45329"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/categories?post=45329"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/tags?post=45329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}